\
&
Contact us
\
&
Contact us
Published on | 1 year ago
Programmes MSCA MSCAThis is a report from the Cluster Event with Marie Skłodowska-Curie Actions (MSCA) Innovative Training Networks (ITN) European Industrial Doctorates (EID). On 10 November 2022, the European Commission European Research Executive Agency (REA) organised a cluster event gathering over 160 actors from 75 MSCA ITN EID projects funded under Horizon 2020. The participants represented both the academic and non-academic sectors, which is essential for this mode of MSCA ITN projects.
A key goal of the meeting was to document successes, good practices and lessons learnt, as well as provide recommendations to help improve and enhance the efficiency and impact of the programme for fellows, industry and academia in the future, thus contributing more effectively to the corresponding EU priorities. These conclusions are also applicable to the MSCA Doctoral Networks (DN) Industrial Doctorates (ID) programme in Horizon Europe.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
